New drug combo targets tough lung cancer in early trial

NCT ID NCT07362940

Recruiting now Disease control Sponsor: Henan Genuine Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two oral drugs, GEN-725 and Dositinib, together in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The trial has two phases: first to find safe doses, then to see if the combination shrinks tumors. About 110 participants will take the drugs daily until their disease worsens or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GEN-725 tablets and Dositinib mesylate tablets
What this could lead to: If successful, this combination could offer a new treatment option for people with a specific type of lung cancer that has not responded to other therapies.
What could go wrong: This is an early-phase trial with only 110 participants, so the benefits are unproven. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China
Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Hospital, Shandong cancer prevention and treatment institute)
NOT_YET_RECRUITING

Jinan, China
Henan Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, China
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITING

Xiamen, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.